Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation.

Leconet W, Liu H, Guo M, Le Lamer-Déchamps S, Molinier C, Kim S, Vrlinic T, Oster M, Liu F, Navarro V, Batra JS, Noriega AL, Grizot S, Bander NH.

Mol Cancer Ther. 2018 Sep;17(9):1927-1940. doi: 10.1158/1535-7163.MCT-17-1138. Epub 2018 Jun 11.

2.

Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis.

Leconet W, Chentouf M, du Manoir S, Chevalier C, Sirvent A, Aït-Arsa I, Busson M, Jarlier M, Radosevic-Robin N, Theillet C, Chalbos D, Pasquet JM, Pèlegrin A, Larbouret C, Robert B.

Clin Cancer Res. 2017 Jun 1;23(11):2806-2816. doi: 10.1158/1078-0432.CCR-16-1316. Epub 2016 Dec 6.

3.

Induction of PSMA and Internalization of an Anti-PSMA mAb in the Vascular Compartment.

Nguyen DP, Xiong PL, Liu H, Pan S, Leconet W, Navarro V, Guo M, Moy J, Kim S, Ramirez-Fort MK, Batra JS, Bander NH.

Mol Cancer Res. 2016 Nov;14(11):1045-1053. Epub 2016 Jul 25.

4.

CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib-resistant chronic myeloid leukaemia.

Gioia R, Trégoat C, Dumas PY, Lagarde V, Prouzet-Mauléon V, Desplat V, Sirvent A, Praloran V, Lippert E, Villacreces A, Leconet W, Robert B, Vigon I, Roche S, Mahon FX, Pasquet JM.

J Pathol. 2015 Sep;237(1):14-24. doi: 10.1002/path.4561. Epub 2015 Jun 4.

PMID:
25965880
5.

HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models.

Thomas G, Chardès T, Gaborit N, Mollevi C, Leconet W, Robert B, Radosevic-Robin N, Penault-Llorca F, Gongora C, Colombo PE, Lazrek Y, Bras-Goncalves R, Savina A, Azria D, Bazin H, Pèlegrin A, Larbouret C.

Oncotarget. 2014 Aug 30;5(16):7138-48.

6.

Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy.

Leconet W, Larbouret C, Chardès T, Thomas G, Neiveyans M, Busson M, Jarlier M, Radosevic-Robin N, Pugnière M, Bernex F, Penault-Llorca F, Pasquet JM, Pèlegrin A, Robert B.

Oncogene. 2014 Nov 20;33(47):5405-14. doi: 10.1038/onc.2013.487. Epub 2013 Nov 18.

7.

Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump.

Mazard T, Causse A, Simony J, Leconet W, Vezzio-Vie N, Torro A, Jarlier M, Evrard A, Del Rio M, Assenat E, Martineau P, Ychou M, Robert B, Gongora C.

Mol Cancer Ther. 2013 Oct;12(10):2121-34. doi: 10.1158/1535-7163.MCT-12-0966. Epub 2013 Aug 19.

8.

Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.

Lazrek Y, Dubreuil O, Garambois V, Gaborit N, Larbouret C, Le Clorennec C, Thomas G, Leconet W, Jarlier M, Pugnière M, Vié N, Robert B, Monnet C, Bouayadi K, Kharrat H, Mondon P, Pèlegrin A, Chardès T.

Neoplasia. 2013 Mar;15(3):335-47.

9.

Nonviral delivery of small interfering RNA into pancreas-associated immune cells prevents autoimmune diabetes.

Leconet W, Petit P, Peraldi-Roux S, Bresson D.

Mol Ther. 2012 Dec;20(12):2315-25. doi: 10.1038/mt.2012.190. Epub 2012 Sep 18.

10.

Preexisting autoantibodies predict efficacy of oral insulin to cure autoimmune diabetes in combination with anti-CD3.

Mamchak AA, Manenkova Y, Leconet W, Zheng Y, Chan JR, Stokes CL, Shoda LK, von Herrath M, Bresson D.

Diabetes. 2012 Jun;61(6):1490-9. doi: 10.2337/db11-1304. Epub 2012 Feb 23.

Supplemental Content

Loading ...
Support Center